Antinuclear antibodies in patients on anticonvulsant therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear; D000927:Anticonvulsants / Q000009:adverse effects*; D002220:Carbamazepine / Q000009:adverse effects; D002467:Cell Nucleus / Q000276:immunology; D003168:Complement Fixation Tests; D004247:DNA; D000939:Epitopes; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000009:adverse effects; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009698:Nucleoproteins; D011324:Primidone / Q000009:adverse effects; D012995:Solubility; D013950:Thymus Gland / Q000276:immunology; D014376:Tuberculosis / Q000188:drug therapy
D000974:Antibodies, Antinuclear; D000927:Anticonvulsants; D000939:Epitopes; D006827:Hydantoins; D009698:Nucleoproteins; D011324:Primidone; D002220:Carbamazepine; D004247:DNA; D007538:Isoniazid